Detailed results from the phase 3 TEMPO trials show tavapadon offers a mechanistically distinct approach for managing motor ...
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials ...
AbbVie Inc. (NYSE:ABBV) ranks among the top picks for a retirement portfolio. The FDA received a New Drug Application from AbbVie Inc. (NYSE:ABBV) on September 26 for tavapadon, an experimental oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results